Edwards PVT Trial
This article was originally published in The Gray Sheet
Executive Summary
FDA and Irvine, Calif. firm's discussions on resuming the company's PVT percutaneous aortic valve feasibility trial have included modifying patient enrollment goals from the original protocol, CEO Michael Mussallem indicated in a July 21 Q2 earnings call. Edwards still plans to begin enrollment by year-end for the study that will incorporate an updated valve delivery system (1"The Gray Sheet" June 20, 2005, p. 17)...
You may also be interested in...
Canadian Study Prompts Edwards To Rethink PVT Feasibility Trial
Edwards Lifesciences intends to resume a U.S. PVT percutaneous aortic valve feasibility trial by year-end
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.